Table 2.

Changes in the aqueous cytokine levels in patients with PVRL after 1-month intravitreal MTX treatment.

	Baseline	After 1 month of treatment	P-value
IFN-γ (pg/mL)	8.17 ± 14.23	0.55 ± 0.67	0.015
IL-2 (pg/mL)	1.55 ± 0.82	1.07 ± 0.63	0.099
IL-6 (pg/mL)	139.21 ± 152.44	957.54 ± 2334.34	0.552
IL-10 (pg/mL)	6592.41 ± 7641.88	21.98 ± 1.84	0.001*
IL-12 (pg/mL)	20.85 ± 24.87	1.84 ± 2.53	0.002*
IL-17 (pg/mL)	9.52 ± 15.93	3.82 ± 1.73	0.530
TNF-α (pg/mL)	27.45 ± 25.33	2.92 ± 3.05	0.001*
IL-10/IL-6 ratio	141.23 ± 244.71	0.98 ± 1.45	0.001*

Data are presented as mean ± standard deviation. PVRL, primary vitreoretinal lymphoma.

MTX methotrexate, IFN-γ interferon gamma, IL interleukin, TNF-α tumor necrosis factor alpha.

*P < 0.007.